General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT07061977

Background Information

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). The primary objective of this study is to determine whether induction immunotherapy (IO) and chemotherapy prior to concurrent chemoradiation therapy (CCRT) + IO improves progression-free survival (PFS) compared to CCRT+IO alone.

For more information visit: https://clinicaltrials.gov/study/NCT07061977

Offered At

Inova Schar Cancer Institute
A division of Inova Fairfax Hospital
8081 Innovation Park Drive 
Fairfax, VA 22031
Principal Investigator

Leslie Randall, MD

Eligibility Information

  • Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma
  • Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement
  • No prior definitive surgical, radiation, or systemic therapy for cervical cancer.
  • Not Pregnant and Not Nursing
  • ECOG Performance Status of ≤ 2

Ineligibility Information

N/A